Becton Dickinson (NYSE:BDX) said last Friday it is lifting former C.R. Bard science, technology and clinical affairs senior VP John DeFord to the role of chief technology officer and exec VP. Since acquiring Bard in a $24 billion deal that closed last December, DeFord has served as BD interventional segment R&D SVP, the Franklin Lakes, N.J.-based company […]